From the Journals

CSF Proteomics Identifies New Biomarkers for Multiple Sclerosis

Large-cohort CSF proteomics from the Mann Lab identifies a 22-protein panel distinguishing MS from related diseases

  • By

  • March 11, 2026

  • 3 min

Share

A recent study by the Max Planck Institute of Biochemistry has revealed a 22-protein panel that enhances multiple sclerosis (MS) diagnosis, particularly for patients who lack traditional biomarkers. Utilizing advanced mass spectrometry techniques, researchers processed a large cohort of over 5,000 individuals, identifying distinct protein signatures that differentiate MS from other inflammatory neurological diseases. This innovative approach not only improves diagnosis but also offers prognostic insights regarding disease progression, indicating its potential applications in other neurological conditions.

Original Source(s)

CSF Proteomics Identifies New Biomarkers for Multiple Sclerosis

Large-cohort CSF proteomics from the Mann Lab identifies a 22-protein panel distinguishing MS from related diseases

  • March 11, 2026

  • 3 min

Related Content

Sudden Vision Loss: Could It Be Pituitary Apoplexy?

Case report highlights delayed treatment and persistent visual loss in a patient with pituitary adenoma

FDA Approves Therapy for Cerebral Folate Deficiency

Decision addresses a rare neurologic disorder linked to folate transport impairment.

Blood Test Forecasts Alzheimer's Onset

Plasma p-tau217 “clocks” estimate timing of symptoms years before clinical diagnosis

  • March 9, 2026

  • 2 min